Aldoxorubicin may be safe, effective for advanced soft-tissue sarcoma
the ONA take:
Single-agent aldoxorubicin, a novel albumin-binding prodrug of doxorubicin, showed superior efficacy over doxorubicin and manageable adverse effects in patients with advanced soft-tissue sarcoma, a new study published online ahead of print in JAMA Oncology has shown.
For the international, multicenter, open-label, phase 2b study, researchers enrolled 126 patients with previously untreated locally advanced, unresectable, or metastatic soft-tissue sarcoma. Participants were randomly assigned 2:1 to receive aldoxorubicin 350 mg/m2 or doxorubicin 75 mg/m2 administered intravenously once every 3 weeks for up to six cycles.
Results showed that median progression-free survival was significantly improved with aldoxorubicin compared with doxorubicin. In addition, 6-month progression-free survival rates and tumor response rates were significantly improved with aldoxorubicin.
In regard to safety, no acute cardiotoxic effects were observed with either treatment, but left ventricular ejection fraction less than 50% occurred in 3 of 40 patients who received doxorubicin. Grade 3 or 4 neutropenia occurred more frequently in the aldoxorubicin group.
The findings suggest that further investigation of aldoxorubicin therapy in advanced soft-tissue sarcoma is warranted.
Single-agent aldoxorubicinshowed superior efficacy over doxorubicin and manageable adverse effects in advanced soft-tissue sarcoma.
- Prehabilitation Program Improves Preoperative Fitness in Patients With Colorectal Cancer
- Acupuncture Improves Postoperative Symptoms in Women Undergoing Surgery for Breast Cancer
- Combination of Gemcitabine and New CHK1 Inhibitor Is Effective in Soft Tissue Sarcomas
- Alcohol Consumption, Particularly White Wine, Associated With Increased Risk of Melanoma
- LIVESTRONG Exercise Program Improves QoL in Cancer Survivors
- Exercise is as Effective in Treating Metastatic Prostate Cancer as Medication
- Walnut Consumption Changes Gut Microbiome, Decreases Growth of Colon Cancer in Mice
- Vaccine Enters Phase I Study for Safety and Effectiveness in Multiple Myeloma
- Timing Chemotherapy Administration to Circadian Rhythm Improves Drug Effectiveness
- New Therapy Blocks Breast Cancer Cells From Entering and Hiding in Bone Marrow to Form Latent Metastases
- Costs, Complications Higher for Women Who Undergo Second Surgery After BCS
- Omitting RT in Certain Older Women With Early Breast Cancer is Safe
- Fluorescent Nanoparticles Represent Novel Detection Method of HER2 Expression
- Assessment of Stromal Features in DCIS Requires Robustness
- Profile of Tivantinib and its Potential in the Treatment of Hepatocellular Carcinoma: the evidence to date
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|